TGA approval for ResApp’s wearable device for cough monitoring

ASX-listed digital health company ResApp Health has received TGA approval to list its new wearable device for monitoring cough on the Australian Register of Therapeutic Goods (ARTG).

The device, which has also received CE Mark certification allowing it to be manufactured and sold in Europe, is initially aimed at the clinical trial market to measure cough frequency but is also expected to be used as a platform for monitoring at-risk patients with COPD or asthma.

Posted in Australian eHealth

Tags: ResApp Health

You need to log in to post comments. If you don't have a Pulse+IT website account, click here to subscribe.

Sign up for Pulse+IT eNewsletters

Sign up for Pulse+IT website access

For more information, click here.

Copyright © 2022 Pulse+IT Communications Pty Ltd
No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher.
Supported by Social Media Agency | pepperit